Quantcast
Channel: GSK – European Pharmaceutical Review
Browsing index pages (26 articles)
↧

Image may be NSFW.
Clik here to view.

Current trends in freeze-drying

Controlled nucleation is one of the most topical trends in the industry, as the freezing step is of paramount importance for stability of products. The temperature range between 0°C and the real...

View Article


Image may be NSFW.
Clik here to view.

Sir Andrew Witty to retire as CEO of GSK

GSK has announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017. Sir Andrew Witty CREDIT: GSK GSK’s Board has agreed that he will retire...

View Article


Image may be NSFW.
Clik here to view.

GSK’s Advair Diskus achieves primary endpoint in LABA safety study

GSK has announced results from the paediatric ‘LABA’ (long acting beta2-agonist) safety study. The VESTRI study compared Advair Diskus (FSC), a combination of the LABA, salmeterol, and the inhaled...

View Article

Image may be NSFW.
Clik here to view.

GSK presents data on of Nucala in asthma patients stratified by eosinophil...

Data from a post-hoc study show that severe asthma patients with a baseline blood eosinophil count of 150 cells/μL or above who received GSK’s Nucala (100mg fixed dose subcutaneous injection of...

View Article

Image may be NSFW.
Clik here to view.

Maternal immunisation

Childhood vaccination was one of the most significant medical success stories of the 20th century with vaccines making diseases such as measles, whooping cough and rubella much more unlikely. New and...

View Article


Image may be NSFW.
Clik here to view.

CMA fines pharmaceutical companies £45 million

The UK Competition and Markets Authority (CMA) has fined a number of pharmaceutical companies for anti-competitive conduct and agreements in relation to the supply of paroxetine. The CMA’s decision...

View Article

Image may be NSFW.
Clik here to view.

GSK submits sBLA seeking expanded indication for Flulaval Quadrivalent

GSK has submitted a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) for Flulaval Quadrivalent (Influenza Vaccine). This vaccine is currently approved for...

View Article

Image may be NSFW.
Clik here to view.

Presentation videos from the World’s 1st International Pharmaceutical seminar...

Videos of the presentations from the world’s 1st TRS seminar for quantitative pharmaceutical analysis can be viewed on demand at www.cobaltlight.com/trs100seminar. More than 70 delegates from across...

View Article


Image may be NSFW.
Clik here to view.

GSK initiates Phase 1 study of IONIS-HBV-LRx; Ionis gets milestone payment

Ionis Pharmaceuticals has announced that GSK has initiated a Phase 1 study of IONIS-HBV-LRx. IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the...

View Article


Image may be NSFW.
Clik here to view.

Comic Relief and GSK team up to help fight malaria

Comic Relief and GSK are teaming up in support of global efforts to strengthen health systems’ capabilities to fight malaria. A new fund – created through a £17m donation from GSK and £5m from Comic...

View Article

Image may be NSFW.
Clik here to view.

Amgen reacquires product rights to 3 products from GSK

Amgen has entered into a definitive agreement with GSK to reacquire all of its remaining rights to Prolia (denosumab), XGEVA (denosumab) and Vectibix (panitumumab) in 48 countries. The agreement...

View Article

Image may be NSFW.
Clik here to view.

Phase III study of sirukumab in giant cell arteritis starts

Dosing has commenced in a Phase III study evaluating GSK’s sirukumab, a human anti-interleukin (IL)-6 monoclonal antibody, for the treatment of patients with giant cell arteritis (GCA). GCA is a type...

View Article

Image may be NSFW.
Clik here to view.

GSK announces Phase III results for belimumab in SLE

GSK has announced results from the BLISS-SC Phase III pivotal study of Benlysta (belimumab) administered subcutaneously in patients with active, autoantibody-positive systemic lupus erythematosus...

View Article


Image may be NSFW.
Clik here to view.

GSK and Merck initiate Phase I trial of GSK3174998 with Keytruda

GSK and Merck have announced the initiation of a Phase I clinical trial designed to evaluate GSK’s GSK3174998 as monotherapy and in combination with Merck’s Keytruda (pembrolizumab) in patients with...

View Article

Image may be NSFW.
Clik here to view.

GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles

GSK’s candidate shingles vaccine demonstrates 90% efficacy against shingles, in adults aged 70 years and over. GlaxoSmithKline plc announced today that the second pivotal phase III study of its...

View Article


Image may be NSFW.
Clik here to view.

GSK’s losmapimod cardiovascular study fails

GSK has announced that an interim review of data from part A of its losmapimod phase III study, LATITUDE-TIMI 60, did not indicate efficacy against the primary endpoint and did not support investment...

View Article

Image may be NSFW.
Clik here to view.

CHMP recommends mepolizumab for severe refractory eosinophilic asthma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for GSK’s Nucala (mepolizumab) as an...

View Article


Image may be NSFW.
Clik here to view.

Results from the SUMMIT COPD CV survival study announced

GlaxoSmithKline (GSK) and Theravance have announced initial results from the SUMMIT COPD study for Relvar/Breo Ellipta (fluticasone furoate/vilanterol or FF/VI) 100/25mcg. The study involved 16,485...

View Article

Image may be NSFW.
Clik here to view.

Merial Sas, GSK, Sanofi Pasteur, Nestle Research Center will meet at the...

Microbiological contamination of products and processes continues to be a major concern to the pharmaceutical industry and its regulations. Contamination of an aseptic process can have a serious impact...

View Article

Image may be NSFW.
Clik here to view.

Novartis pays $1 billion to bolster its pipeline with ofatumumab

Novartis is to acquire all remaining rights to ofatumumab from GSK for up to $1 billion plus royalties. Ofatumumab, a fully human monoclonal antibody which targets CD20, is being developed for...

View Article
Browsing index pages (26 articles)


Latest Images